[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100405906":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":242,"collaborators":244,"id":251,"slug":252,"hasResults":253,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":253,"sex":258,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":21,"studyType":264,"phases":265,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":286},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BENRALIZUMAB","EXPERIMENTAL","Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.",[13],"Drug: Benralizumab Prefilled Syringe",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Benralizumab Prefilled Syringe",[9],[20],"Transcriptomic",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"François-Xavier BLANC, MD-PHD","CONTACT","+33240165545","xavier.blanc@chu-nantes.fr",[29,44,55,66,77,88,99,110,119,127,138,150,158,168,179,190,198,209,220,231],{"facility":30,"status":31,"city":32,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Centre hospitalier Intercommunal Aix-en-Provence","RECRUITING","Aix-en-Provence","France","FR",{"type":36,"coordinates":37},"Point",[38,39],5.44973,43.5283,{"lat":39,"lon":38},[42],{"name":43,"role":25,"phone":21,"phoneExt":21,"email":21},"Youssef TRIGUI, MD-PHD",{"facility":45,"status":31,"city":46,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"CHU Angers","Angers",{"type":36,"coordinates":48},[49,50],-0.55202,47.47156,{"lat":50,"lon":49},[53],{"name":54,"role":25,"phone":21,"phoneExt":21,"email":21},"Hakima OUKSEL, MD",{"facility":56,"status":31,"city":57,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"CHU Bordeaux","Bordeaux",{"type":36,"coordinates":59},[60,61],-0.58046,44.84124,{"lat":61,"lon":60},[64],{"name":65,"role":25,"phone":21,"phoneExt":21,"email":21},"Pierre-Olivier GIRODET, MD-PHD",{"facility":67,"status":31,"city":68,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"CHRU Brest","Brest",{"type":36,"coordinates":70},[71,72],-4.48628,48.39029,{"lat":72,"lon":71},[75],{"name":76,"role":25,"phone":21,"phoneExt":21,"email":21},"Raphael LE MAO, MD-PHD",{"facility":78,"status":31,"city":79,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CHU Dijon","Dijon",{"type":36,"coordinates":81},[82,83],5.01391,47.31344,{"lat":83,"lon":82},[86],{"name":87,"role":25,"phone":21,"phoneExt":21,"email":21},"Philippe BONNIAUD, MD-PHD",{"facility":89,"status":31,"city":90,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"CHU Grenoble","Grenoble",{"type":36,"coordinates":92},[93,94],5.71479,45.17869,{"lat":94,"lon":93},[97],{"name":98,"role":25,"phone":21,"phoneExt":21,"email":21},"Christel SAINT-RAYMOND, MD-PHD",{"facility":100,"status":31,"city":101,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Hôpital Bicêtre - AP-HP","Le Kremlin-Bicêtre",{"type":36,"coordinates":103},[104,105],2.36073,48.81471,{"lat":105,"lon":104},[108],{"name":109,"role":25,"phone":21,"phoneExt":21,"email":21},"Marc HUMBERT, MD-PHD",{"facility":111,"status":112,"city":113,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":114,"geoPoint":118,"contacts":21},"CH Mans","WITHDRAWN","Le Mans",{"type":36,"coordinates":115},[116,117],0.20251,48.0021,{"lat":117,"lon":116},{"facility":120,"status":112,"city":121,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":122,"geoPoint":126,"contacts":21},"CHU Lille","Lille",{"type":36,"coordinates":123},[124,125],3.05512,50.63391,{"lat":125,"lon":124},{"facility":128,"status":31,"city":129,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Hospices Civils de Lyon","Lyon",{"type":36,"coordinates":131},[132,133],4.84789,45.74906,{"lat":133,"lon":132},[136],{"name":137,"role":25,"phone":21,"phoneExt":21,"email":21},"Gilles DEVOUASSOUX, MD-PHD",{"facility":139,"status":140,"city":141,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Assistance Publique des Hôpitaux de Marseille","NOT_YET_RECRUITING","Marseille",{"type":36,"coordinates":143},[144,145],5.38107,43.29695,{"lat":145,"lon":144},[148],{"name":149,"role":25,"phone":21,"phoneExt":21,"email":21},"Pascal CHANEZ, MD-PHD",{"facility":151,"status":112,"city":152,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":153,"geoPoint":157,"contacts":21},"CHU Montpellier","Montpellier",{"type":36,"coordinates":154},[155,156],3.87635,43.61093,{"lat":156,"lon":155},{"facility":159,"status":31,"city":160,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"CHU Nantes","Nantes",{"type":36,"coordinates":162},[163,164],-1.55336,47.21725,{"lat":164,"lon":163},[167],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},{"facility":169,"status":31,"city":170,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"CHR Orléans","Orléans",{"type":36,"coordinates":172},[173,174],1.90407,47.90248,{"lat":174,"lon":173},[177],{"name":178,"role":25,"phone":21,"phoneExt":21,"email":21},"Sylvie DRUELLE",{"facility":180,"status":31,"city":181,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Hôpital Bichat - AP-HP","Paris",{"type":36,"coordinates":183},[184,185],2.3488,48.85341,{"lat":185,"lon":184},[188],{"name":189,"role":25,"phone":21,"phoneExt":21,"email":21},"Camille TAILLE, MD-PHD",{"facility":191,"status":112,"city":192,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":193,"geoPoint":197,"contacts":21},"CHU Rouen","Rouen",{"type":36,"coordinates":194},[195,196],1.09932,49.44313,{"lat":196,"lon":195},{"facility":199,"status":31,"city":200,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"CHU Strasbourg","Strasbourg",{"type":36,"coordinates":202},[203,204],7.74553,48.58392,{"lat":204,"lon":203},[207],{"name":208,"role":25,"phone":21,"phoneExt":21,"email":21},"Naji KHAYATH, MD",{"facility":210,"status":31,"city":211,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Hôpital FOCH","Suresnes",{"type":36,"coordinates":213},[214,215],2.22929,48.87143,{"lat":215,"lon":214},[218],{"name":219,"role":25,"phone":21,"phoneExt":21,"email":21},"Colas TCHERAKIAN, MD-PHD",{"facility":221,"status":31,"city":222,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"CHU Toulouse","Toulouse",{"type":36,"coordinates":224},[225,226],1.44367,43.60426,{"lat":226,"lon":225},[229],{"name":230,"role":25,"phone":21,"phoneExt":21,"email":21},"Laurent GUILLEMINAULT, PD-PHD",{"facility":232,"status":31,"city":233,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"Médipôle Hôpital Mutualiste de Villeurbanne","Villeurbanne",{"type":36,"coordinates":235},[236,237],4.8795,45.76601,{"lat":237,"lon":236},[240],{"name":241,"role":25,"phone":21,"phoneExt":21,"email":21},"Jean-Marc DOT, MD-PHD",{"type":243,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[245,248],{"name":246,"class":247},"AstraZeneca","INDUSTRY",{"name":249,"class":250},"Ministère de la Santé - France","UNKNOWN","100405906","phase-4-predictive-signature-of-benralizumab-response-100405906",false,"NCT04565483","Predictive Signature of Benralizumab Response","BENRAPRED","Inclusion Criteria:\n\n* Patients between 18 and 75 years old.\n* Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.:\n\n  * asthma requiring high doses of ICS (\\>1000 microgram per day of Beclomethasone or equivalent) associated with LABA and\u002For systemic corticosteroids to be controlled over one year,\n  * and\u002For uncontrolled asthma despite the later medications,\n  * and\u002For a controlled asthma worsening after decreasing medications,\n* Documented historical reversibility of FEV1 ≥12% and FEV1 gain ≥ 200 milliliter\n* ACQ-7 score ≥ 1,5 at M0.\n* ≥ 3 exacerbations in the 12 months prior to screening visit M-1.\n* Eosinophil blood count ≥ 0,3 G\u002FL at inclusion visit or in the 12 months prior to the inclusion visit. If eosinophil blood count is ≥ 0,15 G\u002FL and \\\u003C 0,3 G\u002FL, an eosinophilic phenotype defined by at least 1 of the following criteria will be required:\n\n  * Fractional Exhaled Nitric Oxide (FeNO) \\> 25 ppm at inclusion visit or in the 12 months prior to the inclusion visit.\n  * Sputum eosinophils ≥ 3% at inclusion visit or in the 12 months prior to the inclusion visit.\n* Patients who provide written informed consent prior to participation in the study\n\nExclusion Criteria:\n\n* Patients diagnosed with difficult-to-treat asthma and\u002For with uncontrolled asthma differential diagnosis according to the judgment of the investigator (e.g., vocal cord dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis, obstructive sleep apnea syndrome, hyperventilation syndrome, allergic broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma\u002FCOPD overlap syndrome).\n* Non-adherent patients to inhaled treatment (ICS + LABA).\n* Active smokers or former smokers exceeding 20 packs year.\n* Exacerbation at inclusion visit M0.\n* Active malignancy or malignancy in remission over less than 5 years.\n* Active parasitic infection or parasitic infection in the past 24 weeks.\n* Hypersensitivity to Benralizumab or to any of the excipients of Fasenra® (histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20)\n* Patients requiring other immunosuppressive and immunomodulator drugs\n* Patients requiring other biotherapy than Benralizumab, with or without French's marketing authorisation in severe asthma\n* Patients requiring other biotherapy than Benralizumab that affects the immune system\n* SARS-COV2 infection\n* Pregnancy, lactation, or patients with childbearing potential refusing efficient contraceptive method.\n* Patients under psychiatric condition altering their comprehension and their ability to give informed consent.\n* Patients already enrolled in a clinical interventional research.\n* Patients not affiliated to a health insurance plan\n* Patients under guardianship, curators or safeguard of justice","ALL","18 Years","75 Years",{"count":262,"type":263},220,"ESTIMATED","INTERVENTIONAL",[266],"PHASE4","The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients.\n\nThis trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)",[269,270],"Asthma; Eosinophilic","Severe Asthma",[272,273,274,275,276],"severe asthma","therapeutic monoclonal antibody","personalized medicine","transcriptomic","biomarkers","2024-04-25",{"date":279,"type":280},"2024-04-26","ACTUAL",{"date":282,"type":280},"2021-10-11",{"date":284,"type":263},"2026-11",{"name":5,"class":6},20]